Suppliers and packagers for generic pharmaceutical drug: TRANEXAMIC ACID

TRANEXAMIC ACID

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	CYKLOKAPRON	tranexamic acid	INJECTABLE;INJECTION	019281	NDA	Pfizer Laboratories Div Pfizer Inc	0013-1114-15	1 AMPULE in 1 CARTON (0013-1114-15) / 10 mL in 1 AMPULE (0013-1114-01)	1986-12-30
Pfizer	CYKLOKAPRON	tranexamic acid	INJECTABLE;INJECTION	019281	NDA	Pfizer Laboratories Div Pfizer Inc	0013-1114-21	10 VIAL in 1 BOX (0013-1114-21) / 10 mL in 1 VIAL (0013-1114-20)	1986-12-30
Am Regent	TRANEXAMIC ACID	tranexamic acid	INJECTABLE;INJECTION	201885	ANDA	American Regent, Inc.	0517-0960-01	1 VIAL, GLASS in 1 CARTON (0517-0960-01) / 10 mL in 1 VIAL, GLASS	2011-11-15
Am Regent	TRANEXAMIC ACID	tranexamic acid	INJECTABLE;INJECTION	201885	ANDA	American Regent, Inc.	0517-0960-10	10 VIAL, GLASS in 1 CARTON (0517-0960-10) / 10 mL in 1 VIAL, GLASS	2011-11-15
Amneal Pharms Co	TRANEXAMIC ACID	tranexamic acid	INJECTABLE;INJECTION	208840	ANDA	Amneal Pharmaceuticals LLC	70121-1398-1	1 VIAL, SINGLE-DOSE in 1 CARTON (70121-1398-1) / 10 mL in 1 VIAL, SINGLE-DOSE	2017-02-28

TRANEXAMIC ACID: GLOBAL SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report analyzes the global supply chain for tranexamic acid, a synthetic lysine derivative used to treat or prevent excessive blood loss. Key manufacturers, their production capacities, and geographical distribution are identified. The analysis covers patent landscapes and regulatory considerations impacting supply.

What is Tranexamic Acid and Its Market Significance?

Tranexamic acid (TXA) is a widely used antifibrinolytic agent. Its primary mechanism of action involves competitively inhibiting the activation of plasminogen to plasmin. Plasmin is a critical enzyme in the fibrinolytic system, responsible for breaking down fibrin clots. By preventing excessive fibrinolysis, TXA stabilizes blood clots and reduces bleeding.

The drug has demonstrated efficacy across various medical settings. It is a standard treatment for heavy menstrual bleeding, a critical component in managing trauma-induced hemorrhage, and used perioperatively to minimize blood loss during surgery. Its application extends to treating bleeding associated with specific medical conditions, such as hereditary angioedema.

The global market for tranexamic acid is substantial, driven by its established therapeutic value, expanding indications, and increasing demand in both developed and emerging economies. The drug's availability in oral and intravenous formulations further contributes to its broad utility. Market growth is influenced by factors including rising incidence of bleeding disorders, advancements in surgical procedures, and the drug's cost-effectiveness compared to alternatives for certain indications.

Who are the Major Manufacturers of Tranexamic Acid?

The production of tranexamic acid involves several key global manufacturers. These companies operate specialized chemical synthesis facilities to produce the active pharmaceutical ingredient (API).

• BOC Sciences: A supplier of pharmaceutical intermediates and APIs.
• ChemSrc: A platform listing chemical suppliers, including those for tranexamic acid.
• Hubei Biocause Pharmaceutical Co., Ltd.: A significant producer based in China.
• Nantong Yongan Pharmaceutical Co., Ltd.: Another prominent Chinese manufacturer.
• Sichuan Jinshi Pharmaceutical Co., Ltd.: A manufacturer contributing to global supply.
• Taiyuan Active Pharmaceutical Factory: Operates within China's pharmaceutical manufacturing sector.
• Vesta Pharmaceuticals Pvt. Ltd.: An Indian manufacturer.
• Xian Shunbang Pharmaceutical Co., Ltd.: Based in China.
• Zhuhai Furen Pharmaceutical Group Co., Ltd.: A diversified pharmaceutical group with TXA production capabilities.

These entities represent a significant portion of the global API supply. Production capacity varies among these manufacturers, with Chinese companies often holding substantial output volumes.

What are the Geographical Distribution and Production Capacities?

The manufacturing of tranexamic acid API is concentrated in specific regions, primarily Asia.

• China: This region is the dominant manufacturing hub, housing a majority of the global production capacity for tranexamic acid API. Companies in China benefit from established chemical synthesis infrastructure and often competitive production costs. The scale of production in China is critical to meeting global demand.
• India: India also plays a role in the global supply chain, with several pharmaceutical companies producing tranexamic acid. Indian manufacturers are known for their API production capabilities and adherence to international quality standards.
• Europe and North America: While significant for formulation and finished drug products, the large-scale API manufacturing of tranexamic acid is less prevalent in these regions compared to Asia. Production in these areas may focus on specialized grades or cater to specific regional regulatory requirements.

Exact global production capacities are proprietary and fluctuate based on market demand and individual company investments. However, industry estimates suggest that the combined capacity of manufacturers, particularly in China, is sufficient to meet current global demand, with potential for expansion. Market intelligence reports indicate that global annual production capacity for tranexamic acid API likely exceeds 5,000 metric tons.

What is the Patent Landscape for Tranexamic Acid?

The patent landscape for tranexamic acid itself is largely mature, with fundamental patents having expired decades ago. However, patent activity continues around novel formulations, delivery methods, and new therapeutic uses.

• Composition of Matter Patents: Original patents covering the tranexamic acid molecule have long expired. This allows for generic manufacturing by any qualified producer.
• Process Patents: Patents may exist for specific, novel, or improved methods of synthesizing tranexamic acid. These patents protect innovative manufacturing processes that offer advantages in terms of yield, purity, or cost-efficiency. For example, patents might detail specific catalysts, reaction conditions, or purification techniques.
• Formulation Patents: Innovation is ongoing in developing new pharmaceutical formulations of tranexamic acid. This includes extended-release oral formulations, specific topical applications, or novel parenteral preparations designed to improve patient compliance, efficacy, or reduce side effects.
• Method of Use Patents: Patents are frequently filed for new therapeutic indications or optimized treatment regimens for tranexamic acid. This can include its use in specific surgical contexts, in combination with other drugs, or for treating previously unaddressed bleeding conditions.

Companies actively engaged in R&D for tranexamic acid-based products seek to secure intellectual property through these newer patent categories to gain market exclusivity for their specific innovations.

What are the Regulatory Considerations for Tranexamic Acid Production and Supply?

Regulatory compliance is paramount for tranexamic acid manufacturers to ensure product quality, safety, and market access.

• Good Manufacturing Practices (GMP): All manufacturers of tranexamic acid API must adhere to GMP standards established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. GMP ensures that products are consistently produced and controlled according to quality standards. This includes rigorous controls over raw materials, manufacturing processes, quality control testing, and documentation.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities like the FDA. A DMF contains confidential, detailed information about the manufacturing, processing, packaging, and storing of the API. This allows regulatory bodies to review the API's quality when a finished drug product application (e.g., an Abbreviated New Drug Application - ANDA) referencing the DMF is submitted.
• Pharmacopoeial Standards: Tranexamic acid API must meet the quality standards outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur.), and the Japanese Pharmacopoeia (JP). These monographs specify purity limits, assay requirements, and identification tests.
• Quality Control and Testing: Manufacturers must implement comprehensive quality control programs. This involves testing raw materials, in-process samples, and the final API to ensure it meets all specified quality attributes. Testing typically includes assays for purity, identification, related substances, residual solvents, and heavy metals.
• Supply Chain Security and Traceability: Regulatory agencies increasingly emphasize supply chain security. Manufacturers and distributors must ensure the integrity of the supply chain, prevent counterfeiting, and maintain traceability of the API from its origin to the finished dosage form manufacturer.

Compliance with these regulations is essential for any company seeking to supply tranexamic acid API to regulated markets.

What are the Key Challenges and Opportunities in the Tranexamic Acid Supply Chain?

The tranexamic acid supply chain faces several challenges and presents distinct opportunities for stakeholders.

Challenges:

• Geopolitical Risks: The concentration of API manufacturing in a few countries, particularly China, creates supply chain vulnerability to geopolitical tensions, trade disputes, or regional disruptions.
• Quality Control Consistency: Ensuring consistent API quality across diverse manufacturing sites globally is a perpetual challenge. Variations in GMP adherence or analytical testing can lead to batch failures or regulatory scrutiny.
• Raw Material Sourcing: The production of tranexamic acid relies on specific chemical precursors. Fluctuations in the availability or price of these raw materials can impact API production costs and lead times.
• Regulatory Hurdles: Navigating the complex and evolving regulatory landscapes in different global markets requires significant investment and expertise. Changes in pharmacopoeial standards or GMP requirements can necessitate process modifications.
• Price Volatility: Market competition among API suppliers can lead to price volatility, impacting the profitability of manufacturers and the cost structure for finished drug product companies.

Opportunities:

• Diversification of Supply: Companies are actively seeking to diversify their API sourcing to mitigate geopolitical risks. This creates opportunities for manufacturers in other regions, such as India, to expand their market share.
• Process Innovation: Developing more efficient, sustainable, or cost-effective synthesis processes for tranexamic acid can provide a competitive advantage and potentially lower production costs.
• New Therapeutic Indications: Research into novel uses for tranexamic acid, such as in neurological conditions or for specific types of cancer-related bleeding, could expand market demand.
• Advanced Formulations: Development of improved drug delivery systems, such as long-acting injectables or specialized topical formulations, can create value and command premium pricing.
• Vertical Integration: Companies may explore vertical integration, from raw material sourcing through API manufacturing to finished dosage form production, to gain greater control over the supply chain and margins.
• Increased Demand in Emerging Markets: Growing healthcare access and infrastructure in emerging economies are expected to drive increased demand for essential medicines like tranexamic acid.

Key Takeaways

• Tranexamic acid API production is primarily concentrated in China, with India also serving as a significant supplier.
• Key manufacturers include Hubei Biocause, Nantong Yongan, and Vesta Pharmaceuticals.
• While core patents have expired, innovation continues in formulations and new therapeutic uses, reflected in ongoing patent filings.
• Strict adherence to GMP, pharmacopoeial standards, and DMF filing is critical for regulatory compliance and market access.
• Supply chain risks are associated with geographical concentration, but opportunities exist in process innovation, diversification, and new market applications.

Frequently Asked Questions

1. What are the primary chemical precursors used in the synthesis of tranexamic acid? The synthesis of tranexamic acid typically begins with materials like cyclohexanecarboxylic acid or related derivatives, which undergo several chemical transformations including nitration, reduction, and amination to form the final molecule.

2. How does the regulatory status of tranexamic acid API differ between major markets like the US and EU? While both the US FDA and the EMA require GMP compliance and often DMF submissions, specific submission requirements and review timelines can vary. Mutual recognition agreements and differing pharmacopoeial standards can also influence regional approvals.

3. What is the typical lead time for procuring large quantities of tranexamic acid API from Asian manufacturers? Lead times can range from 4 to 12 weeks, depending on the manufacturer's current production schedule, raw material availability, and the quantity ordered. Urgent orders may incur premium pricing.

4. Are there any significant environmental concerns associated with the manufacturing process of tranexamic acid? As with many chemical synthesis processes, potential environmental concerns include the management of chemical waste, solvent recovery, and emissions control. Responsible manufacturers implement waste treatment and emission reduction technologies to comply with environmental regulations.

5. What impact do advancements in anticoagulant therapies have on the market for tranexamic acid? While anticoagulants aim to prevent clot formation or growth, tranexamic acid works by stabilizing existing clots and preventing their premature breakdown. Therefore, its role in managing acute bleeding events, heavy menstrual bleeding, and perioperative hemostasis remains distinct and largely unaffected by advancements in broader anticoagulant markets.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/good-manufacturing-practice-gmp [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/partners-networks/good-manufacturing-practice [3] United States Pharmacopeia. (n.d.). USP-NF. Retrieved from https://www.usp.org/products/usp-nf [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia [5] Various chemical supplier databases and industry reports (e.g., ChemSrc, chemical market intelligence platforms).